Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

Most major stock indexes across the globe ended the week higher, following record high gains on the Wall Street. Broader ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The anti-inflammatory drugs market size has grown rapidly in recent years. From $136.86 billion in 2024, it is predicted to ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.